Why SAINT® Is Setting New Standards for Patient Recovery

Those living with depression that hasn’t responded to medication already know the feeling: another prescription, another six-to-eight-week wait to see if it works, another disappointment if it doesn’t. For many people with depression, that cycle can stretch on for years.

Clinicians see this too, from the other side of the exam room. Watching a patient exhaust first- and second-line therapies without relief, with fewer and fewer options left to offer, is one of the hardest parts of treating depression.

SAINT for depression was built for exactly this gap. It combines personalized brain imaging with an accelerated treatment schedule to offer a rapid, non-invasive path to remission, especially for people who haven’t found relief elsewhere. 

Moving Beyond Conventional Depression Care

To understand why SAINT represents a shift, it helps to look at where standard depression care often falls short.

Oral antidepressants often take weeks to have any effect, and even then, they don’t work for everyone — a 2023 reanalysis of real-world patient data found the cumulative remission rate after four treatment trials was closer to 35%, roughly half the rate originally reported.¹ Many people also experience systemic side effects, like weight gain or emotional blunting, that lead them to stop taking their medication before it’s had a chance to help. (For a closer look at other options in this category, see our guide to antidepressant alternatives.)

Standard Transcranial Magnetic Stimulation (TMS) takes a different approach, using magnetic pulses to stimulate the brain instead of medication. But conventional TMS typically requires daily clinic visits for at least 6 weeks — a serious time commitment for busy professionals, rural residents, or anyone in the middle of a severe depressive episode. Standard TMS also tends to rely on general external scalp measurements to find its stimulation target, effectively treating every brain the same way rather than accounting for a person’s unique neuroanatomy.

SAINT was designed to address both of these limitations at once: speed and precision.

What Is SAINT for Depression?

SAINT starts with a personalized functional MRI (fMRI) scan. Unlike a standard MRI, fMRI captures real-time brain activity, allowing clinicians to see how different networks involved in mood and emotional regulation communicate with one another in a specific person’s brain.

From there, a proprietary algorithm analyzes the scan to identify the precise, optimal location for stimulation, removing the guesswork that comes with standardized, one-size-fits-all targeting.

Once that target is set, treatment uses neuromodulation: a safe, localized method that works by helping restore a natural rhythm to underactive neural pathways associated with depression. In simple terms, SAINT doesn’t just stimulate the brain in general. It stimulates the right part of an individual person’s brain, based on their own neural map. (For more on the science behind this, see how SAINT changes the brain.)

A New Standard for Recovery: Clinical Remission in Days, Not Weeks

Where SAINT most clearly breaks from convention is in its timeline. Treatment consists of ten individual 10-minute stimulation sessions per day, spaced out by comfortable 50-minute rest periods, over five consecutive business days. That’s it. No months of daily visits, no long wait to find out if it’s working. 

Curious what that week actually looks like day to day? Here’s what to expect during SAINT treatment

In a double-blind, randomized controlled trial, SAINT achieved a 79% remission rate within that five-day treatment window.² A separate open-label study found that participants reached remission in an average of just 2.6 days.³

For clinicians, this creates a genuinely useful referral option. Sending a treatment-resistant patient for a focused, five-day course of SAINT means they can return to regular therapy or maintenance care already in a markedly improved, more receptive clinical state, rather than continuing to cycle through options that haven’t worked.

It’s worth being clear about who SAINT is for: it’s FDA-cleared specifically for adults with treatment-resistant Major Depressive Disorder (clinical unipolar depression) who have not achieved satisfactory improvement from prior antidepressant medication.

Proof in Practice

Statistics like these are meaningful, but they only tell part of the story. Behind every remission rate is someone who spent years feeling like they’d tried everything.

Deirdre Lehman was one of them. After decades of managing severe depression, bipolar disorder, and a mental health crisis that put her at risk of suicide, she received SAINT through a clinical trial. Within a day of treatment, she described her mind as calmer than it had been since she was a teenager. Read Deirdre’s full story to see what recovery with SAINT can look like — or visit our Patients page to hear directly from others who’ve been through it.

Frequently Asked Questions

A New Path Forward

Chronic depression shouldn’t mean spending months or years waiting for a treatment that might not work. With personalized, non-invasive care, a new path forward in brain health is here.

Find a verified SAINT provider near you.

The SAINT® neuromodulation system is indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. The SAINT neuromodulation system is contraindicated for: patients with non-removable conductive, ferromagnetic, or other magnetic-sensitive metal anywhere in the head or within 30cm of the stimulation coil; patients who have an active or inactive implanted device; or patients with increased intracranial pressure or intracardiac lines, intravenous pumps, or dose calculators. Consult product labeling for a complete list of contraindications, warnings, and precautions. Side effects including headache, fatigue, anxiety, and treatment-site discomfort were shown in clinical trials. Risks associated with transcranial magnetic stimulation, including seizure and worsening depression or suicidality, may exist. Results may vary.

References

1. Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol. BMJ Open. 2023;13(7):e063095.
2. Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry. 2022;179(2):132–141.
3. Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. Am J Psychiatry. 2020;177(8):716–726.